Japanese Pharmacology & Therapeutics（JPT）
Vol. 53 No. 3 2025
■ ORIGINAL ARTICLES
Safety and efficacy of long‒term therapy of sucroferric oxyhydroxide in patients with hyperphosphatemia in chronic kidney disease undergoing dialysis
―Post‒marketing surveillance of P‒TOL® chewable tablets（Final report）―
H. Endo, et al.
Jpn Pharmacol Ther 2025 53（3）213-31
The bone mineral density is related to muscle mass, but not insulin secretion or insulin resistance
―Retrospective study―
I. Hanamura, et al.
Jpn Pharmacol Ther 2025 53（3）233-41